and systolic blood pressures, both higher in men in the placebo group. The end-points (sudden death, fatal and nonfatal myocardial infarction) were significantly reduced by the drug in patients with both angina and infarction; a similar trend was observed in the angina group. Patients with only myocardial infarction did not benefit, those on clofibrate being affected by a higher rate of fatal infarcts. These findings are contradictory and the trial is inconclusive. Likewise, no relationship between beneficial effects and lowering of serum cholesterol may be inferred from it.
The Coronary Drug Project is a national collaborative study to assess long-term therapies which influence lipid metabolism. It is conducted on a sample population of men, aged 30-64 years who have recovered from one or more myocardial infarcts. In such a study, 3~08 patients were treated with either clofibrate, nicotinic acid or placebo, and followed for approximately eight years. Total and cause-specific mortalities were not affected by clofibrate. There was a statistically significant excess of angina pectoris, cardiac arrhythmias, intermittent claudication and nonfatal cardiovascular events in the drug group as compared with the placebo one. The research group concluded that there is no evidence that justifies recommending the use of clofibrate in the treatment of coronary heart disease (Coronary Drug Project Research Group 1975) .
The results of an important international trial in the primary prevention of ischaemic heart disease are now available. The study is based on IS 745 men studied for an average period of 5.3 years (Committee of Principal Investigators 1978). All the statistical difference between the treated and the control high-cholesterol groups is accounted for by the difference in the incidence of nonfatal myocardial infarctions, which was significantly lower in the clofibratetreated group. No differences were found between both groups regarding fatal infarctions, sudden death or incidence of angina pectoris. An adverse important finding was that there' were significantly more deaths from noncardiovascular diseases (liver, gallbladder, small and large intestines) in the clofibrate group than in the control group; there is no clear explanation for this finding which remains a reason for concern.
Dipyridamole Cerebrovascular disease A controlled study was conducted by Acheson et al. (1969) on 169 patients classified in the same diagnostic groups as for their clofibrate study: transient ischaemic attacks, single stroke and multiple strokes. A first treatment period with 400 mg a day lasted 14 months, after which the patients remaining in the study (14 died and 16 had been eliminated because of noncompliance) were followed for a further II months on 800 mg daily. The incidence of ischaemic attacks and recurrence of stroke was not affected by the drug nor was any difference detected between both dosage regimes. The natural history of the disease remained unchanged through the study.
Ischaemic heart disease
Similar deceptive results (Gent et al. 1968) were obtained in 103 patients with acute myocardial infarction. After a treatment period of 4 weeks (400 mg daily) the recorded mortality in the dipyridamole group was 15.7% (8 patients) and 5.8% (3 patients) in the control group. Though the higher mortality in the dipyridamole group could be influenced by the fact that more patients received the drug within the first 48 hours after infarction, as 74.8% of all patients (41 drug-treated, 36 placebo-treated) were admitted within the first three days after infarction it is unlikely that this would have influenced the final negative results.
Prosthetic heart valves
The value of the drug combined with anticoagulants in preventing thromboembolic events in 39 patients who had undergone successful insertions of mitral or aortic valve prostheses was evaluated against a retrospective assessment of 29 patients exclusively on anticoagulants (Arrants & Hairston 1972) . Results suggest that the combination was more effective in preventing arterial emboli and death than anticoagulants alone. Unfortunately changes in the design of the valves which bias the results in favour of dipyridamole were introduced during thẽ t udy. The control group studied retrospectively is also unsatisfactory and the results may not e accepted as conclusive.
similar study with a placebo group (Sullivan et al. 1971) included 163 patients (all oñ ntl coagul ants) controlled during 12 months following valve replacement. Emboli developed III 14% of the placebo-treated subjects but only in 1.3%of the dipyridamole group. Moreover, ne of the patients on the drug died of embolic accidents, whilst two deaths were recorded in t o~e on placebo. The results of this well-conducted trial are conclusive as far as the antlthrombotic effect of the drug combined with anticoagulants is concerned, but no conclusion may be drawn regarding the antithrombotic effects of dipyridamole alone. A retrospective study on the differences in the num ber of carotid transient ischaemic attacks aSSociated with antiplatelet therapy strongly suggested that aspirin could be of value iñ re~enti ng these type of attacks (Dyken et al. 1973 ). The histories of 117 patients admitted urmg the previous 3! years with a diagnosis of transient ischaemic attacks were reviewed. After rigorous criteria were established for the selection of true transient ischaemic episodes, only 26 patients (22%) remained in the study, of which IS had been treated with 600 mg a daỹ f aspirin. Whilst 9 out of the II patients not receiving the drug had an additional attack, only Out of the 15 on the drug suffered from a further episode. There was no difference in the nUl11ber of recorded deaths and infarctions.
wo flaws reduce the reliability of this study: it is retrospective and the average follow-up p~nod for the patients receiving aspirin was 14 months as against 29 months for those not on t e drug. This large difference may have reduced the number of attacks recorded in the aspirin group compared with the non-treated group.
T~e results of an excellent prospective controlled study (against placebo) were recently PUbhshed (Fields et al. 1977) . The objectives were to determine whether treatment with aspirin Would reduce or prevent transient ischaemic attacks (including amaurosis fugax) and result in a reduction in the incidence of mortality and cerebral and retinal infarctions. The analysis of thẽ al 11Pl e as a whole (178 patients) at the end of the study did not reveal a significant difference etween both treatments. .The data were then stratified for two variables: (I) history of transient ischaemic attacks (smgle versus multiple episodes); (2) presence or absence of anatomic lesions appropriate to the presenting clinical picture (complete occlusion of the carotid artery was defined as a nonappropriate lesion). The data from patients with multiple episodes and from those with anatomic lesions appropriate to their symptomatology revealed statistical significance for the absolute end-points in favour of aspirin. An analysis of the cumulative probabilities of death Or nonfatal cerebral or retinal infarction showed that patients with multiple ischaemic attacks re at a significantly higher risk than those with single attacks. These results stress the Il11portance of making a clinical distinction between single and multiple attacks, let alone of a Correct diagnosis of the causative lesion. A careful patient selection is essential before deciding upon antiplatelet therapy. The Canadian co-operative trial of platelet-suppressing drugs in transient cerebral ischaemia P~hents who had experienced at least one episode of transient ischaemia in the three months pno r. to entry were admitted into one of four therapeutic groups: aspirin (1300 mg);
Ul Phl l l pyrazone (800 mg); bot~drugs; placebo ; and they were followed for at least one year.
. ollow-up data from 585 patients were examined for three events: number of transient I~ch~emic attacks, stroke, and death. The overall preliminary analysis showed that aspirin SIgnIficantly reduced the risk of the three events, whilst sulphinpyrazone was of no benefit. The effect on stroke and death was positive for both drugs, though significant only for aspirin. Both were effective (not significantly) on single transient ischaemic attacks; aspirin benefited the patients with multiple attacks, reducing the risk of stroke or death by one third. These positive findings for aspirin apply only to normotensive men, as the drug was apparently ineffective among women and hypertensive patients. Both these findings need to be further clarified before any conclusion can be drawn in respect of high-risk patients and high responders to therapy.
Deep venous thrombosis
The effectiveness of aspirin in the prophylaxis of venous thromboembolism was studied in patients undergoing total hip replacement (Harris et al. 1977) . Before operation, 95 patients were assigned to treatment with aspirin (1200 mg) or placebo. Thromboembolism developed in 45% of the non-treated but only in 25% of those on the drug. This protection was limited to men-a difference between sexes similar to that observed by the Canadian Co-operative Study Group (1978) . Most female patients in the study were postmenopausal and none were on contraceptive medications; hence, the interpretation of this different response is even more difficult.
These results in venous thrombosis should be treated with caution and not extended to other types of venous diseases; as the authors rightly stress, hip surgery involves direct trauma to veins which may exaggerate the contribution of platelets to venous thrombosis.
Cardiovascular disease
Two large independent survey studies (Boston Collaborative Drug Surveillance Group 1974) in which information was obtained on regular drug intake before admission and on discharge diagnoses, involved 776 patients (treated in hospital and discharged as acute myocardial infarction) and almost 14000 controls. A negative association between regular aspirin intake and nonfatal myocardial infarction was shown for patients with a first infarct as well as for those with a recurrent episode.
In the field of secondary prevention of mortality from myocardial infarction, a study based on 1126patients followed for 2 years (Elwood et al. 1974) showed that the mortality rate in the placebo group was always higher than in the aspirin group (though not reaching statistical significance). This study, however, suffers from a number of flaws: halfway through, the code was broken and the results disclosed; the age restriction of 65 years was removed; the interval between infarction and admission was changed from less than four weeks to six months or more; the group admitted earlier in the study consisted disproportionately of men from one specific area (a 'geographical' effect may hence not be discarded); the compliance is unknown, and it could be that the dose of aspirin (300 mg a day) was too low.
In the Coronary Drug Project aspirin study, with results based on 1529patients with a prior history of myocardial infarction, followed for an average of 22 months, the overall mortality was 5.8% in the aspirin group and 8.3% in the placebo group (Coronary Drug Project Research Group 1976) . This difference of 30% is only suggestive and not large enough to be conclusive. Furthermore, only men with a prior history of oestrogen or dextrothyroxine therapy were included in this study, which precludes from extending these findings to other populations.
Sulphinpyrazone

Cerebrovascular disease
The study on patients with amaurosis fugax (Evans 1972), though well controlled is not conclusive. Twenty patients were randomly allocated to start treatment on either sulphinpyrazone (800 mg) or placebo, and then crossed over to the other therapeutic group, each treatment period lasting six weeks. Baseline numbers of attacks were similar for both groups. Subjects first treated with placebo showed no change from these, but when crossed over to sulphinpyrazone the incidence of attacks fell. The group first treated with the drug showed a reduction of the number of attacks, which rose when they received placebo. Thirteen subjects improved on the drug who did not improve whilst on placebo; all subjects who had improved on placebo also improved on sulphinpyrazone.
Though these results are statistically highly significant, no short-term trial in a clinical condition which is itself so variable may be regarded as conclusive. Doubts were also raised egarding the correct diagnosis and selection of patients: this is not an easy condition to Identify and the 20 patients were recruited in a short time by a single centre.
General arterial disease
T~e longevity study by Blakely & Gent (1975) showed that the survival of elderly male patients WIth a history of myocardial infarction, stroke and/or peripheral arterial disease could be prolonged by sulphinpyrazone. Out of 291 patients closely monitored for 4 years, 166 had a previous history of arterial disease. Sulphinpyrazone (600 mg) significantly reduced the total mortality in this group, remaining without effect in the patients without arterial disease. The benefit was even more striking when only deaths from vascular causes were taken into consideration. Unfortunately the cause of death was not accurately determined in all cases. These results may be applied only to a similar high risk group but should not be extended to the general population.
Platelet survival
In clinical conditions such as transient cerebral ischaemic attacks (Steele et al. 1977) , rheumatic heart disease (Steele et al. 1974 ), hypoxaemia and pulmonary hypertension (Steele et al. 1977) , substitute heart valves (Steele et al. 1975) , recurrent venous thrombosis (Steele et al. 1973) and coronary artery disease (Steele et al. 1975 ), platelet survival time was consistently shortened and significantly increased after treatment with 800 mg of sulphinpyrazone for periods ranging from 5 weeks to 38 months.
Steele and his colleagues obtained dramatic clinical improvement in 7 patients with recurrent venous and arterial thrombosis, despite that platelet survival was normalized in only two. These authors also treated 19 patients with transient cerebral ischaemia for an average period of 30 months (six patients served as controls). The drug significantly increased platelet survival and a marked beneficial effect on the frequency of ischaemic attacks was observed in 10 patients, whilst a further 6 had a reduction of attacks by at least one half of pre-treatment levels (Steele et al. 1977) .
. ,
Arteriovenous-shunt thrombosis
In patients on renal dialysis (Kaegi et al. 1975) 600 mg a day of sulphinpyrazone significantly red~ced the number of thrombi per patient-month. Significance was reached for male patients, whIlst only a trend in favour of the drug was recorded in females.
Similar results were confirmed by Michie & Wombolt (1977) , who also found this therapeutic difference (which remains unexplained) between males and females.
Cardiovascular disease
It is perhaps in this field that the most exciting progress has been made. The initial results of a stUdy in the prevention of cardiac mortality after a first myocardial infarct (Anturane Reinfarction Trial Research Group 1978) represent data accumulated on 1475 eligible patients entered at 25-35 days after myocardial infarction. There were 69 deaths of which 68 were of ardiac nature and 1 was cerebrovascular. For cardiac deaths the annual death rate was 9.5% In the placebo group and 4.9% in the sulphinpyrazone group; this represents a reduction of 48.5%. When the annual sudden cardiac death rate is analysed (sudden death being defined as that occurring within 60 minutes of the onset of symptoms) this rate was of 6.3% for the placebo group and 2.7% for the sulphinpyrazone one, representing a reduction of 57.2%.
Discussion
The only study in cerebrovascular disease with clofibrate did not produce evidence as to the effectiveness of the drug and it is difficult to assume that patients without hypercholesterolaemia would have benefited from treatment. Despite the claimed beneficial effect of the drug in coronary disease, this was not confirmed by the well conducted study by the Coronary Drug Project Research Group (1975) . The results' of the international trial in coronary ischaemic disease (Committee of Principal Investigators 1978)confirmed the basic hypothesis that reduction of high serum cholesterol can reduce the incidence of ischaemic heart disease, though the validity ofthis affirmation seems to be restricted to nonfatal infarctions. The results of this study are basically in agreement with the negative findings of the Coronary Drug Project, and clofibrate may not be recommended as a lipid-lowering drug for the primary prevention of coronary heart disease.
Regarding dipyridamole, the total absence of effect on major end-points in cerebrovascular disease is disheartening, and inadequate designs of other trials preclude from drawing valid conclusions in this field. It has been proven effective when combined with anticoagulants in preventing thromboembolic accidents after cardiac valve replacements. The usefulness of the drug in improving the prognosis in ischaemic heart disease is unknown and the results of the Persantin-Aspirin Reinfarction Study should be awaited before trying to answer this question.
The evidence that aspirin is helpful and beneficial in thromboembolic diseases is growing, but further results where major end points are unequivocally affected are required in ischaemic heart disease. Evidence is good regarding its effectiveness in transient ischaemia and deep venous thrombosis; in the field of coronary disease, results of ongoing studies such as the Aspirin Myocardial Infarction Study (USA) and a one-year study under the supervision of the Medical Research Council (UK) should be available in the course of the next two years and may clarify the current situation.
Sulphinpyrazone has been extensively evaluated in cerebrovascular and cardiovascular diseases and a number of clinical studies strengthen the evidence that platelet survival time is the most reliable test for evaluating the progress of arterial thromboembolic disease. In the field of transient cerebral ischaemia, indications that the drug might be useful are contradictory and weak, whilst there is firmer ground for belief that it is effective in arteriovenous-shunt thrombosis and in improving the general condition of elderly male patients suffering from complications of severe atherosclerosis. It is undoubtedly in coronary disease that sulphinpyrazone looks most promising; the evidence in this field is possibly the most impressive currently at hand for all antiplatelet agents.
Before deciding upon a specific anti thrombotic treatment, careful consideration should be given to patients who seem to be at a higher risk than others. The presence of risk factors seems to affect the efficacy of the drugs in a way which is not yet clearly understood. Patients with multiple transient ischaemic attacks are at a higher risk than those with single episodes; likewise, they apparently respond better to treatment than the latter. This 'high-risk-highresponse' factor is also found in hypertensives versus normotensives, appropriate carotid lesion versus non-appropriate lesion, men versus women. High-risk patients seem to be high responders to treatment, whilst the benefit appears to be fairly poor on low-risk subjects.
Unfortunately the ideal clinical model to test antithrombotic drugs has not yet been found; most if not all clinical trials are carried out on patients whose diseases may be evaluated on a long-term basis only. This is a serious difficulty and it would be helpful if quick and reliable results were obtainable from short-term therapy. Investigations in this field are thus long, difficult and often tedious, but it is to be hoped that ever-increasing interest and research will in the end disclose an ideal and reliable clinical model.
